Antiretroviral News and Research

RSS
Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

Quality HIV/AIDS treatment eased through extended agreement about lowest-priced drugs and diagnostics

Quality HIV/AIDS treatment eased through extended agreement about lowest-priced drugs and diagnostics

AIDS Healthcare Foundation targets GSK over voluntary licensing of its AIDS drug patents in South Africa

AIDS Healthcare Foundation targets GSK over voluntary licensing of its AIDS drug patents in South Africa

How HIV/AIDS treatment can best be combined with community-based care in some of the poorest areas of sub-Saharan Africa

How HIV/AIDS treatment can best be combined with community-based care in some of the poorest areas of sub-Saharan Africa

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV patients treated with antiretroviral therapy early after infection do test negative

HIV patients treated with antiretroviral therapy early after infection do test negative

Increasing levels of growth hormone may be an effective treatment for HIV lipodystrophy

Increasing levels of growth hormone may be an effective treatment for HIV lipodystrophy

Average cost for providing primary care to an HIV-infected patient is $30 USD per visit

Average cost for providing primary care to an HIV-infected patient is $30 USD per visit

Widespread prenatal HIV screening and use of antiretroviral drugs in pregnant HIV-infected women is needed

Widespread prenatal HIV screening and use of antiretroviral drugs in pregnant HIV-infected women is needed

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Nevirapine effective in reducing the risk of transmission of HIV at birth

Nevirapine effective in reducing the risk of transmission of HIV at birth

Cheap AIDS drugs may help prevent HIV in babies in Thailand

Cheap AIDS drugs may help prevent HIV in babies in Thailand

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

Americans give Russia $34.2 million to help treat and care for people living with HIV/AIDS and tuberculosis

Americans give Russia $34.2 million to help treat and care for people living with HIV/AIDS and tuberculosis

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

Women delay AIDS with vitamins B, C and E

Women delay AIDS with vitamins B, C and E

Bush outlines government actions on HIV/AIDS

Bush outlines government actions on HIV/AIDS

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Treatment of cytomegalovirus remains a priority in order to improve the prognosis for people with HIV-1 infection

Treatment of cytomegalovirus remains a priority in order to improve the prognosis for people with HIV-1 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.